Pimavanserin
Phase 3Terminated 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Jan 1, 2017 → May 30, 2024
NCT ID
NCT03121586About Pimavanserin
Pimavanserin is a phase 3 stage product being developed by Acadia Pharmaceuticals for Schizophrenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03121586. Target conditions include Schizophrenia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05796167 | Phase 1 | Withdrawn |
| NCT05357612 | Approved | Recruiting |
| NCT04809116 | Approved | Withdrawn |
| NCT05555615 | Phase 2/3 | Terminated |
| NCT04292223 | Approved | Completed |
| NCT04000009 | Phase 3 | Terminated |
| NCT03623321 | Phase 3 | Completed |
| NCT03482882 | Phase 2 | Completed |
| NCT03118947 | Phase 2 | Completed |
| NCT03121586 | Phase 3 | Terminated |
| NCT03018340 | Phase 2 | Completed |
Competing Products
20 competing products in Schizophrenia